Cardiovascular Pharmacology of the NLRP3 Inflammasome

J Cardiovasc Pharmacol. 2019 Sep;74(3):173-174. doi: 10.1097/FJC.0000000000000725.

Authors

Antonio Abbate¹, George W Booz²

Affiliations

¹ Pauley Heart Center, Wright Center for Clinical and Translation Research, Virginia Commonwealth University, Richmond, VA.
² Department of Pharmacology and Toxicology, School of Medicine, The University of Mississippi Medical Center, Jackson, MS.

PMID: 31498192
DOI: 10.1097/FJC.0000000000000725

No abstract available

Publication types

Editorial
Introductory Journal Article

MeSH terms

Animals
Anti-Inflammatory Agents / pharmacology
Cardiovascular Agents / pharmacology
Cardiovascular Diseases / drug therapy
Cardiovascular Diseases / immunology
Cardiovascular Diseases / metabolism*
Cardiovascular System / drug effects
Cardiovascular System / immunology
Cardiovascular System / metabolism*
Humans
Inflammasomes / antagonists & inhibitors
Inflammasomes / immunology
Inflammasomes / metabolism*
Inflammation / drug therapy
Inflammation / immunology
Inflammation / metabolism*
NLR Family, Pyrin Domain-Containing 3 Protein / antagonists & inhibitors
NLR Family, Pyrin Domain-Containing 3 Protein / immunology
NLR Family, Pyrin Domain-Containing 3 Protein / metabolism*
Signal Transduction

Substances

Anti-Inflammatory Agents
Cardiovascular Agents
Inflammasomes
NLR Family, Pyrin Domain-Containing 3 Protein